EP4294433 - IMMUNOGENIC COMPOSITION, USE AND METHODS [Right-click to bookmark this link] | Status | Examination is in progress Status updated on 14.06.2024 Database last updated on 02.11.2024 | |
Former | Request for examination was made Status updated on 24.11.2023 | ||
Former | The international publication has been made Status updated on 26.08.2022 | ||
Former | unknown Status updated on 11.03.2022 | Most recent event Tooltip | 12.10.2024 | Change: Despatch of examination report + time limit | Applicant(s) | For all designated states GlaxoSmithKline Biologicals SA Rue de l'Institut 89 1330 Rixensart / BE | [2023/52] | Inventor(s) | 01 /
ARORA, Ashwani 53100 Siena / IT | 02 /
CASULA, Daniela 53100 Siena / IT | 03 /
CONTORNI, Mario 53100 Siena / IT | 04 /
ULLOA-MONTOYA, Fernando 1330 Rixensart / BE | 05 /
RONDINI, Simona 53100 Siena / IT | 06 /
SUN, Tian 1330 Rixensart / BE | 07 /
TESTA, Marco 53100 Siena / IT | [2023/52] | Representative(s) | Baker, Suzanne J. GSK Legal & Compliance - Global Patents 79 New Oxford Street London WC1A 1DG / GB | [N/P] |
Former [2023/52] | Baker, Suzanne J. GlaxoSmithKline Global Patents (CN925.1) 980 Great West Road Brentford, Middlesex TW8 9GS / GB | Application number, filing date | 22706807.9 | 18.02.2022 | [2023/52] | WO2022EP54029 | Priority number, date | EP20210158503 | 22.02.2021 Original published format: EP 21158503 | EP20210163667 | 19.03.2021 Original published format: EP 21163667 | [2023/52] | Filing language | EN | Procedural language | EN | Publication | Type: | A1 Application with search report | No.: | WO2022175423 | Date: | 25.08.2022 | Language: | EN | [2022/34] | Type: | A1 Application with search report | No.: | EP4294433 | Date: | 27.12.2023 | Language: | EN | The application published by WIPO in one of the EPO official languages on 25.08.2022 takes the place of the publication of the European patent application. | [2023/52] | Search report(s) | International search report - published on: | EP | 25.08.2022 | Classification | IPC: | A61K39/102, A61K39/104, A61P11/00, A61K39/00 | [2023/52] | CPC: |
A61K39/102 (EP,US);
A61K39/1045 (EP,US);
A61P11/00 (EP,US);
A61K2039/545 (EP);
A61K2039/555 (EP);
A61K2039/55511 (EP);
A61K2039/55566 (EP);
A61K2039/55572 (US);
A61K2039/55577 (US);
A61K2039/57 (EP);
A61K2039/572 (EP);
A61K2039/575 (EP);
| Designated contracting states | AL, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LI, LT, LU, LV, MC, MK, MT, NL, NO, PL, PT, RO, RS, SE, SI, SK, SM, TR [2023/52] | Title | German: | IMMUNOGENE ZUSAMMENSETZUNG, VERWENDUNG UND VERFAHREN | [2023/52] | English: | IMMUNOGENIC COMPOSITION, USE AND METHODS | [2023/52] | French: | COMPOSITION IMMUNOGÈNE, UTILISATION ET PROCÉDÉS | [2023/52] | Entry into regional phase | 15.08.2023 | National basic fee paid | 15.08.2023 | Designation fee(s) paid | 15.08.2023 | Examination fee paid | Examination procedure | 15.08.2023 | Amendment by applicant (claims and/or description) | 15.08.2023 | Examination requested [2023/52] | 15.08.2023 | Date on which the examining division has become responsible | 26.06.2024 | Despatch of a communication from the examining division (Time limit: M06) | Fees paid | Renewal fee | 20.02.2024 | Renewal fee patent year 03 |
Opt-out from the exclusive Tooltip competence of the Unified Patent Court | See the Register of the Unified Patent Court for opt-out data | ||
Responsibility for the accuracy, completeness or quality of the data displayed under the link provided lies entirely with the Unified Patent Court. | Cited in | International search | [A]US2018354996 (BLAIS NORMAND [CA], et al); | [XI]WO2019034575 (GLAXOSMITHKLINE BIOLOGICALS SA [BE]); | [A]US2020046823 (COHET CATHERINE [BE], et al); | [A]WO2021023691 (GLAXOSMITHKLINE BIOLOGICALS SA [BE]) | by applicant | GB2220211 | GB2242134 | WO9118926 | WO9400153 | EP0594610 | WO9517210 | WO9602555 | WO9633739 | EP0689454 | WO0056360 | WO0226757 | WO03050782 | WO03061743 | WO2007012871 | WO2007018463 | WO2007068896 | WO2007084053 | WO2012139225 | WO2015125118 |